Core Insights - Cencora, Inc. is a leading global pharmaceutical-services company with a market cap of $58.7 billion, providing comprehensive solutions in the healthcare supply chain [1][2] Company Overview - Cencora operates in the healthcare value chain, offering services for branded, generic, specialty, and over-the-counter medicines [1] - The company is classified as a large-cap stock due to its market cap exceeding $10 billion, highlighting its significant influence in the medical distribution industry [2] - Cencora's competitive advantage stems from its diversified portfolio, scale-driven bargaining power, and strong brand equity [2] Stock Performance - Cencora's stock has experienced a 7.1% decline from its 52-week high of $377.54, reached on November 25 [3] - Over the past three months, the stock has gained 18.9%, outperforming the Health Care Select Sector SPDR Fund's 12.2% gain [3] - Year-to-date, shares have risen 56.1%, and over the past 52 weeks, they have climbed 40.3%, significantly outperforming the XLV's YTD gains of 12.2% [4] Recent Financial Results - Following the release of strong Q3 results on November 5, Cencora's shares increased by 2.8%, indicating investor confidence [5] - Q3 revenue rose 5.9% year-over-year to $83.7 billion, exceeding Wall Street expectations by 69 basis points [5] - Adjusted EPS for the quarter jumped 15% to $3.84, surpassing consensus estimates by 1.3%, reinforcing the company's growth momentum [5]